288 related articles for article (PubMed ID: 11850914)
21. Poison ivy/oak dermatitis. Part I: Prevention--soap and water, topical barriers, hyposensitization.
Fisher AA
Cutis; 1996 Jun; 57(6):384-6. PubMed ID: 8804839
[No Abstract] [Full Text] [Related]
22. Prevention of poison ivy and poison oak allergic contact dermatitis by quaternium-18 bentonite.
Marks JG; Fowler JF; Sheretz EF; Rietschel RL
J Am Acad Dermatol; 1995 Aug; 33(2 Pt 1):212-6. PubMed ID: 7622647
[TBL] [Abstract][Full Text] [Related]
23. Plant Dermatitis: More Than Just Poison Ivy.
Watchmaker L; Reeder M; Atwater AR
Cutis; 2021 Sep; 108(3):124-127. PubMed ID: 34826273
[TBL] [Abstract][Full Text] [Related]
24. Desensitization to poison ivy.
GROSS ER
Med Times; 1956 Sep; 84(9):921-3. PubMed ID: 13368853
[No Abstract] [Full Text] [Related]
25. POISON IVY EXTRACT, ALUM PRECIPITATED.
WECHSLER HL
JAMA; 1964 Nov; 190():845. PubMed ID: 14202832
[No Abstract] [Full Text] [Related]
26. Poison ivy (Rhus) dermatitis.
Parker GF; Logan PC
Am Fam Physician; 1972 Jul; 6(1):62-6. PubMed ID: 4263952
[No Abstract] [Full Text] [Related]
27. Poison oak hyposensitization. Evaluation of purified urushiol.
Epstein WL; Baer H; Dawson CR; Khurana RG
Arch Dermatol; 1974 Mar; 109(3):356-60. PubMed ID: 4273614
[No Abstract] [Full Text] [Related]
28. Black-spot poison ivy.
Schram SE; Willey A; Lee PK; Bohjanen KA; Warshaw EM
Dermatitis; 2008; 19(1):48-51. PubMed ID: 18346397
[TBL] [Abstract][Full Text] [Related]
29. Influence of oral prednisone on patch-test reactions to Rhus antigen.
Condie MW; Adams RM
Arch Dermatol; 1973 Apr; 107(4):540-3. PubMed ID: 4266825
[No Abstract] [Full Text] [Related]
30. Algerian ivy dermatitis; a California disease.
DORSEY CS
Calif Med; 1959 Feb; 90(2):155-9. PubMed ID: 13629356
[TBL] [Abstract][Full Text] [Related]
31. Prevention of poison ivy dermatitis with oral homeopathic Rhus toxicodendron.
Signore RJ
Dermatol Online J; 2017 Jan; 23(1):. PubMed ID: 28329482
[TBL] [Abstract][Full Text] [Related]
32. An oral antigen preparation in the prevention of poison ivy dermatitis; results in 455 cases of ivy sensitivity.
GROSS ER
Ind Med Surg; 1958 Mar; 27(3):142-4. PubMed ID: 13513172
[No Abstract] [Full Text] [Related]
33. THE MANAGEMENT OF POISON IVY.
LINTON WT
Appl Ther; 1964 Jun; 6():494-7. PubMed ID: 14167335
[No Abstract] [Full Text] [Related]
34. ATTEMPTS TO HYPOSENSITIZE WITH POISON IVY EXTRACTS.
KANOF NB; BAER RL
Ann Allergy; 1964 Apr; 22():161-4. PubMed ID: 14145236
[No Abstract] [Full Text] [Related]
35. Basophilic leukocytes in a case of poison ivy.
Dvorak HF; Mihm MC
N Engl J Med; 1971 Jul; 285(1):54-5. PubMed ID: 4253524
[No Abstract] [Full Text] [Related]
36. CONTACT SENSITIVITY IN RHESUS MONKEYS TO POISON IVY EXTRACTS AND FLUORODINITROBENZENE.
BOWSER RT; KIRSCHSTEIN RL; BAER H
Proc Soc Exp Biol Med; 1964 Dec; 117():763-6. PubMed ID: 14244948
[No Abstract] [Full Text] [Related]
37. Preservation of allergic contact dermatitis to poison ivy (urushiol) in late HIV disease. The implications and relevance to immunotherapy with contact allergens.
Smith KJ; Skelton HG; Nelson A; Wagner KF; Hackley BE
Dermatology; 1997; 195(2):145-9. PubMed ID: 9310722
[TBL] [Abstract][Full Text] [Related]
38. Studies on poison ivy. In vitro lymphocyte transformation by urushiol-protein conjugates.
Dupuis G
Br J Dermatol; 1979 Dec; 101(6):617-24. PubMed ID: 161173
[TBL] [Abstract][Full Text] [Related]
39. Poison ivy (Rhus toxicodendron); a survey of the poison ivy problem in Canada and some independent observations on the value of zirconium products in prophylaxis and treatment.
CASPERS AP
Can Med Assoc J; 1957 May; 76(10):852-60. PubMed ID: 13426931
[No Abstract] [Full Text] [Related]
40. Toxicodendron hyposensitization programs.
Watson ES
Clin Dermatol; 1986; 4(2):160-70. PubMed ID: 2941127
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
